ANNX Trading Analysis - 11/05/2026 12:07 PM — TRU-SENTIMENT

News Headlines & Context

ANNX (Annexon, Inc.) is a clinical-stage immunotherapy company focused on complement-system therapeutics. Recent general-knowledge context for the name includes:

• ANNX has historically moved on clinical trial readouts for its lead complement-inhibitor programs in neuroinflammatory and ophthalmic disorders.
• Biotech small-caps with negative EPS like ANNX are sensitive to financing/cash-burn headlines and sector rotation into or out of speculative healthcare names.
• No verified live X posts were retrieved this run; the only sentiment source is the embedded Delta 40–60 options flow.
• Given the embedded fundamentals show a trailing EPS of -1.15 and no dividend, any catalyst would likely be binary event-driven rather than fundamental earnings growth.
• Contextually, the extreme bullish options flow below contrasts with a technically neutral tape, suggesting a possible event-led positioning rather than trend confirmation.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for ANNX:

• Trailing EPS is -1.15; the company is not profitable (no revenue, margin, or ROE data provided).
• Trailing P/E, forward P/E, PEG ratio, price-to-book, profit margins, debt-to-equity, and free cash flow are all null/unavailable in the data.
• Market cap is $741,253,890 with shares outstanding of 189,579,000 and institutional ownership at 49.11%.
• Dividend yield is 0.00% (no dividend). Beta is 2.31 (highly volatile relative to market).
• 52-week range is $2.54 to $7.18; current price near $4.31 sits in the lower-middle of that range.
• Historical volatility is 73.42%; average volume is 3,678,000 shares.
• No analyst consensus, target mean price, or recommendation key is provided.

Fundamentally, ANNX is a pre-revenue biotech with high beta and no earnings. This diverges from the bullish options sentiment, which is not supported by fundamental strength in the embedded data.

Current Market Position

From the embedded minute and daily data:

• Daily close on 2026-11-04 was $4.31; intraday on 2026-11-05 at 11:35 showed price around $3.92 (last bar close).
• Minute bars show a fade from $4.31 open on 11-04 to $3.92 by 11-05 11:35, indicating short-term weakness.
• Daily 30-day high is $4.52 (2026-11-04), low is $3.36 (2026-10-16); current price is near upper third of range.
• Volume on 2026-11-04 was 3,666,533 vs 20-day avg of 2,608,729 — above-average participation.

Technical Analysis

• Price ($4.31) is above SMA 5 ($4.10), above SMA 20 ($3.89), and above SMA 50 ($4.15) — mild bullish alignment but tight.
• RSI 14 at 66.75 shows bullish momentum but not yet overbought (>70).
• MACD (-0.01) equals signal (-0.01), histogram ~0.00 — no directional momentum confirmation.
• Bollinger upper is $4.29; current daily close $4.31 is just above upper band — short-term extended.
• 30-day range: price sits closer to high ($4.52) than low ($3.36).

True Sentiment Analysis (Delta 40-60 Options)

From the embedded True Sentiment options file (methodology: Delta 40-60 only):

Call Dollar Volume: $1,756,010.00 (100.00%) Put Dollar Volume: $260.00 (0.00%) Total: $1,756,270.00

• Call contracts: 10,045 | Put contracts: 1 — extreme directional call conviction.
• Sentiment flagged: Bullish
• Options spread recommendation file shows "no_recommendation" due to divergence between technicals and sentiment.
• Divergence: options say bullish; MACD/technicals show no clear direction.

Key Price Levels (Observational Only)